COVID-19 vaccines in multiple sclerosis treated with cladribine or ocrelizumab
Fabio Buttari, Antonio Bruno, Ettore Dolcetti, Federica Azzolini, Paolo Bellantonio, Diego Centonze, Roberta Fantozzi
Topics & Concepts
OcrelizumabMedicineCladribineMultiple sclerosisCoronavirus disease 2019 (COVID-19)ImmunologyVaccinationInternal medicineRituximabAntibodyInfectious disease (medical specialty)DiseaseSARS-CoV-2 and COVID-19 ResearchMultiple Sclerosis Research StudiesPolyomavirus and related diseases